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consequence of the fact that the polyketide biosyntheticCofactors in Fatty Acid
pathways in organisms like streptomyces are closelyBiosynthesis—Active Site related and intersect with the fatty acid biosynthetic
pathways (Campbell and Cronan, 2001).Organizers and Drug Targets
The most recently determined structures of enzymes
in the FAS system have been the -ketoacyl-acyl carrier
protein reductase (FabG), which reduces the ACP-linked
-ketoacyl group to a -hydroxyacyl group. StructuresThe structure of E. coli -ketoacyl-acyl carrier protein
of this enzyme have been determined for the Brassicareductase (FabG) in its binary complex with NADPH
Napus (Fisher et al., 2000), M. tuberculosis (Cohen-Gon-reveals how cofactor-induced conformational changes
saud et al., 2002), and E. coli (Price et al., 2001, 2004configure the active site for catalysis. It provides an-
[this issue of Structure]) FabGs, all of which are compo-other target for drug design in the fatty acid biosynthe-
nents of type II FAS systems. FabG utilizes NADPH tosis pathway.
reduce the -keto group, and structures of the cofactor
binary complexes of Brassica Napus and E. coli en-It has been over 40 years since the components of the
zymes and of the apoenzymes of M. tuberculosis andfatty acid biosynthesis pathway were identified and 20
E. coli have been determined. In this issue of Structure,years since the detailed mechanisms of the steps of this
the structure of the binary cofactor complex of E. coliessential pathway in bacteria and eukarya were worked
FabG with NADP is described. Through comparison ofout. The multiple enzyme activities that catalyze the
this complex with the apoenzyme and with a point mu-steps of fatty acid synthesis, collectively called fatty
tant structure, a complex set of conformational changesacid synthase (FAS), are closely similar in all organisms
induced by cofactor binding is revealed. These changes
(Figure 1). Variations in fatty acid product profiles among
assemble the Ser-Tyr-Lys catalytic triad and also a water
organisms arise from altered reactant specificities of
chain that is adduced to play an essential role as a
the otherwise similar enzymes of the pathway, rather proton wire in restoring the catalytic conformation at
than from alternative pathways. The enzymes of the FAS the end of the reaction. These conformational changes
pathway exist in two forms, called I and II, which are also suggest a basis for the coordinated positive (acyl-
distinguished by the polypeptide chain connectivity of ACP) and negative (NADPH) cooperativity of the tetra-
the constituent enzymes. The type I FAS is an obligate meric FabG coupled to NADPH binding.
homodimer of multifunctional monomers, while the type It is noteworthy in this FabG binary complex structure
II FAS is composed of discrete enzymes that correspond that binding of the nucleotide and nicotinamide moieties
functionally, and probably also structurally, to the func- of NADPH are inferred to occur sequentially and that
tional domains of the type I FAS. The type I FAS occurs the participation of the NADP cofactor in catalysis is
in animals and yeast and the type II FAS predominates not limited to chemistry in the nicotinamide ring. The
in bacteria, though there are organisms (e.g., M. tuber- structure of the Tyr151Phe mutant in complex with
culosis) (Bloch, 1977) that carry both types of FAS. NADP shows that the nucleotide of NADP binds in the
In the past 10 years, representative structures of all same way as in the wild-type, but the nicotinamide and
enzymes and carrier proteins of type II FAS systems ribose groups are disordered. The implication is that the
have been determined. This recent interest in the struc- nucleotide binds first and subsequent conformational
tures of the FAS enzymes stems from the appreciation changes create the nicotinamide binding site and the
that the FAS system has several characteristics that catalytic configuration at the active site. Comparison of
make it an attractive target for drug design: indispens- the Tyr151Lys mutant binary complex structure with that
ability, preexisting bacteriostatic drugs (isoniazid, triclo- of the wild-type points to multiple critical roles for the
san) that target this pathway, and the distinction be- ribose hydroxyl groups of NADP in organizing the active
tween the animal type I and bacterial type II FASs, which site residues and in catalysis. These hydroxyl groups
offers the possibility of specificity in the design of anti- form hydrogen bonds to the Tyr151 and Lys155 residues
bacterials. There are relatively few natural product inhib- of the catalytic triad and also are part of the proton wire
itors of fatty acid biosynthesis (cerulenin, thiolac- extending from the ordered water chain that is essential
for catalytic turnover.tomycin), and it has been suggested that this is a
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Figure 1. Outline of the Fatty Acid Biosynthe-
sis Pathway in E. coli
Enzymes, in red, are as follows:
MCAT (FabD)—malonyl CoA: ACP transa-
cylase
ER (FabI)—enoyl ACP reductase
DH (FabA)—-hydroxyacyl-ACP reductase
KAS (FabH, FabB, FabF)—-ketoacyl ACP
synthase
KR (FabG)—-ketoacyl ACP reductase
This intimate involvement in catalysis of parts of the sence of knowledge about the protein conformational
NADP cofactor structure beside the nicotinamide ring changes accompanying cofactor binding. Perhaps drug
invites comparison with the two best characterized and designers should direct more effort toward targeting
widely used drugs that disrupt microbial fatty acid bio- enzyme-cofactor complexes like that of FabG with
synthesis, isoniazid and triclosan. Both of these com- NADP, factoring in the conformational changes of the
pounds interact with the NAD binding site of the other enzyme and the multiple unique roles of the cofactor
reductase in the fatty acid biosynthesis pathway, the itself.
enoyl-acyl carrier protein reductase, FabI. Isoniazid is
a pro-drug that must undergo activation to a free radical
H. Tonie Wrightprior to its acylation of the NAD radical generated dur-
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